Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02203903 · ClinicalTrials.gov registry record · Phase 1
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
A Phase 1 study of Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS, sponsored by Catherine Bollard.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT02203903 is a Phase 1 study of Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS that is actively recruiting participants, run by Catherine Bollard. The registered enrollment target is 50 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT02203903, a Phase 1 study of Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS, is actively recruiting participants, sponsored by Catherine Bollard.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients with high risk AML and MDS.
Interventions
- BIOLOGICAL Tumor associated antigen lymphocytes (TAA-T)
Study Locations (2)
District of Columbia
- Childrens National Medical Center - Washington D.C.
Maryland
- Tania Jain, MD - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-01-01 |
| Est. Completion | 2027-06-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02203903
The ClinicalTrials.gov registry entry for NCT02203903 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Catherine Bollard, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS appearing as the primary indexed condition, and to 1 intervention - of which Tumor associated antigen lymphocytes (TAA-T) is the first listed.
NCT02203903 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT02203903 about?
NCT02203903 is a clinical study titled "Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies". This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients with high risk AML and MDS.
What is the current status of trial NCT02203903?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2015-01-01. Estimated completion is 2027-06-28.
What conditions does trial NCT02203903 study?
This clinical trial studies the following conditions: Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS.
What interventions are being tested in trial NCT02203903?
The interventions under investigation include: Tumor associated antigen lymphocytes (TAA-T) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02203903?
This trial is sponsored by Catherine Bollard, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02203903 being conducted?
This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS
All registered trials for this condition
District of Columbia
All trials with a study site in District of Columbia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.